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Mesenchymal stem cells (MSCs) are multipotent non-haematopoietic cells primarily 
originating from within the bone marrow. Physiologically they aid in the process of wound 
healing. However, MSCs are also recruited by cancer cells to the tumour stroma where they 
have been shown to alter cancer cell proliferation, angiogenesis and metastasis.  
There is no clear answer as to whether bone marrow-MSCs (BM-MSCs) aid or inhibit the 
metastasis of breast cancer cells. Given that 600+ woman die each year in NZ from metastatic 
breast cancer the need for a better understanding as to what influences breast cancer metastasis 
is critical. The purpose of our study was to use in vitro techniques to better understand the 
metastatic processes that the secretome of BM-MSCs may influence, and to further determine 
whether BM-MSCs aid or inhibit breast cancer metastasis.  
Conditioned media (CM) was generated by culturing BM-MSCs in serum free media for 1 or 5 
days. This was then used in various in vitro experiments that simulate the cellular events of 
metastasis. These include cell migration, cell adhesion and cell invasion. Two breast cancer cell 
lines were used, the MDA-MB-231 and MCF-7 cell lines.  
BM-MSC CM was found to significantly increase the migration of the MDA-MB-231 cell line 
up to 180 ± 4.0% of untreated control (p < 0.001) in the Boyden chamber cell motility model. 
BM-MSC CM also increased the migration of the MCF-7 cell line in this same model, although 
not significantly. In a scratch assay, MDA-MB-231 cell motility was enhanced and cells were 
visibly elongated by the BM-MSC CM. BM-MSC CM appeared to restore the adhesion of the 
MCF-7 cells to fibronectin, increasing adhesion from 53.8 ± 5.8% to 112.4 ± 18.4% of uncoated 
control (p < 0.05). Cell invasion was not significantly altered in either cell line. From these 
results, it was concluded that BM-MSC CM primarily acts to enhance breast cancer cell 
migration. This helps understand how MSCs enhance the metastatic spread of breast cancer 
cells as shown in previous in vivo studies.  
Additional to understanding the possible metastatic processes BM-MSCs influence, a major 
focus of our study was to investigate the validity of the in vitro experimental models. Cell 
viability was assessed and BM-MSCs were not found to significantly alter the viability of either 
cell line in a manner that would confound the results seen in the Boyden chamber studies. The 
relevance of using healthy MSCs in culture compared to those that would be found in the 
tumour microenvironment was also investigated. BM-MSCs were cultured in breast cancer CM 
and then used in the Boyden chamber the same way normal MSCs were. Activated MSCs were 
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seen to significantly enhance the migration of both MDA-MB-231 and MCF-7 cells to 112 ± 
0.4% and 189.5 ± 20.0% of normal MSC control (p < 0.01 and p < 0.05, respectively). This 
shows that healthy MSCs in culture are not necessarily representative of those found in the 
tumour microenvironment and that simple techniques, like the one developed in our study, 
designed to make MSCs more relevant to those in the tumour microenvironment, will help make 
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Chapter 1. Introduction 
1.1 Stromal Cells and the Tumour Microenvironment 
Stroma is a term used to describe the non-epithelial cells which in non-pathological situations 
maintain epithelial cell normality. Examples of such cells are fibroblasts, various immune cells 
and pericytes. Non-cellular components include the extra cellular matrix (ECM) which is 
comprised of structural proteins like collagen, fibronectin and laminin. Both the non-cellular 
and the cellular component make up the microenvironment which supports the homeostatic 
maintenance of epithelial tissue such as the major organs (Joyce et al., 2009). 
During cancer development, these same components become a part of the tumour 
microenvironment. A tumour is consequently composed of cancer cells and the surrounding 
stromal cells and ECM. The population of stromal cells in the microenvironment include 
pericytes, immune cells, endothelial cells, activated fibroblasts and mesenchymal stem cells 
(MSCs) (Fig. 1) (Korkaya et al., 2011). These cells co-develop with the cancer cells and each 
different cell type contribute in different ways that aid or inhibit the progression of the tumour. 
This is achieved primarily via the secretion of certain cytokines, growth factors and proteases 
from the stromal cells which then signal to the cancer cells(Korkaya et al., 2011). Because of 
Figure 1. The tumour microenvironment (Joyce et al., 2009). 
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this many studies have focused on elucidating the signalling provided by individual stromal cell 
types in order to properly understand their influence and importance in cancer pathology.  
1.2 Mesenchymal Stem Cells 
MSCs are multipotent non-haematopoietic cells primarily originating from within the bone 
marrow. MSCs are most commonly involved in aiding the process of wound healing where they 
migrate from the bone marrow to the site of injury. However, in vivo imaging studies have 
confirmed the presence of MSCs at the site of tumours in various cancer models (Karnoub et 
al., 2007; Kidd et al., 2009; Liu et al., 2011). Karnoub et al. (2007) established xenograft breast 
cancer tumours in mice and 2 weeks later injected GFP-labeled MSCs into the circulation of 
these animals. Ten days later when the animals were sacrificed, the tumours, lungs, kidneys and 
liver were removed. Fluorescent microscopy revealed the presence of GFP-MSCs in only the 
primary xenograft tumour and the metastatic nodules in the lungs. Similar selective 
accumulation of MSCs to wound areas has also been observed, linking the comparable 
influence of tumours and wounds to attract MSCs (Kidd et al., 2009).  
MSCs can be extracted from a number of other various tissues including the peripheral blood 
and adipose tissue (Hass et al., 2011). They are classified by the expression of the surface 
markers CD105, CD72 and CD90 and their ability to differentiate into either adipocytes, 
osteoblasts and chondrocytes (Baird, 2015). 
As MSCs are a multipotent stem cell they can contribute multiple cell populations to the tumour 
stroma including fibroblasts and pericytes (Ishii et al., 2003; Wang et al., 2016a). Studies have 
shown that up to 40% of the stromal fibroblasts are of MSC origin which highlights the 
significant role MSCs can play in the composition of the tumour stroma (Ishii et al., 2003). And 
although research has made it clear MSCs have the ability to differentiate into pericytes, the 
extent to which they may contribute to the tumour microenvironment is yet unknown (Roorda 
et al., 2009; Wang et al., 2016a).  
1.2.1 Migration of MSCs to the tumour microenvironment 
In 1986, Harold Dvorak hypothesed that ‘tumours are wounds that do not heal’ (Dvorak, 1986). 
He was referring to the similarities between the stromal cells present surrounding a tumour and 
those found in the granulation tissue of healing wounds. It has since been shown that cancer 
cells produce similar signalling to injured tissue and therefore recruit similar cell populations. 
This is how MSCs come to be present in the microenvironment (Spaeth et al., 2008). Like 
wound healing, the chemotactic migration of MSCs from the bone marrow to the tumour is 
facilitated by the release of cytokines, chemokines, growth factors and proteases from the 
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cancer cells. Research into these pathways has revealed a multitude of secreted factors involved. 
These include, but are not limited to, chemokine ligand 7 (CXCL-7), hepatoma derived growth 
factor, Cyclophilin B, vascular endothelial growth factor, stromal cell-derived factor-1, 
interleukin-8, transforming growth factor-β1, monocyte chemoattractant protein-1, 
neurotrophin-3 and urokinase plasminogen activator (Birnbaum et al., 2007; Dwyer et al., 
2007; Gutova et al., 2008; Lin et al., 2008; Kalwitz et al., 2009). Once exposed to these 
mediators, MSCs undergo changes in the expression of proteins related to cell migration, cell 
adhesion and matrix remodelling, which plays a role in their movement towards the source of 
the chemoattractants.  
Kalwitz et al. (2009) demonstrated this well in a study that exposed bone marrow- derived 
MSCs to the chemokine CXCL7. One thousand nM of CXCL7 was added to the growth media 
of cultured MSCs. Following this, microarray analysis revealed that, compared to untreated 
MSCs, there was a marked increase in the expression of migration genes (CXCL1-3,-5,-6,-8 
and -11) and matrix remodelling genes (Matrix Metalloproteinase-1 and -13 (MMP)). In fact, 
when MMP-1 is silenced the migration of MSCs is noticeably reduced, indicating the important 
role it plays in MSC migration (Ho et al., 2009). 
Once at the tumour microenvironment, the MSCs are exposed to the factors present in the 
tumour microenvironment. These factors include the inflammatory cytokine tumour necrosis 
factor- α (TNF-α), which has been shown to influence the behaviour of the MSCs and make 
them pro-tumourigenic, increasing the ability of MSCs to enhance cancer cell migration and 
invasion (Shin et al., 2010).  
1.2.2 Influence of MSCs on cancer pathology 
As previously mentioned, MSCs influence a number of different key cancer pathologies. Most 
studies seeking to understand these influences use a combination of co-culture in vitro and in 
vivo experiments. However, more often than not the in vitro results do not match the in vivo. 
Between research groups the in vivo results often disagree despite the appearance of similar 
experimental protocols. An explanation for this variation could be the difficulty in 
characterising MSCs, resulting in highly variable cell populations and therefore incomparable 
results (Baird, 2015). Results may also be inconsistent due to the multiple origins of the MSCs 
used, for example from bone marrow or adipose tissue. Du et al. (2016) covered this well in a 
study that revealed the heterogeneity of the proliferation and angiogenic response of endothelial 
cells to conditioned media (CM) from 4 different types of MSC. Additionally, each type of 
MSC was shown to behave differently when assessed for tube formation capabilities. Because 
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of this it is important to focus on a certain MSC type when considering the effects they exert 
on cancer cells. For the present study, bone marrow derived MSCs (BM-MSCs) were the cell 
of interest. Therefore, discussion of the influence of MSCs on cancer characteristics within this 
section will focus only on studies that used BM-MSCs.  
It is important to note that MSCs do communicate with cancer cells in a number of different 
ways. This occurs both directly and indirectly (Melzer et al., 2016). Indirect communication is 
achieved via the secretion of various factors by the MSCs whilst direct contact is made through 
cell to cell contact usually achieved via Notch receptors, gap junctions or similar surface 
receptors (Melzer et al., 2016).  
1.2.2.1 Influence on cancer cell proliferation 
Enhanced proliferation is one of the common hallmarks of a cancer cell (Hanahan et al., 2011). 
When the breast cancer cell line MDA-MB-231 was directly co-cultured with BM-MSCs in 
vitro (40:60 ratio), cell proliferation was found to increase by 39% when compared to 
monoculture (Mandel et al., 2013). A549 lung cancer cell proliferation was also significantly 
increased (p < 0.05) in a similar in vitro co-culture model with BM-MSCs (Wang et al., 2016b). 
In vivo models additionally support the pro-proliferative influence of BM-MSCs. When 
NOD/scid mice were subcutaneously (sc) injected with MDA-MB-231 cells mixed with BM-
MSCs (40:60 ratio), the resulting tumours, 23-days later, were 10-fold larger than those tumours 
in animals injected with MDA-MB-231 cells alone (Mandel et al., 2013). 
Immunohistochemistry also found that those tumours containing BM-MSCs had a notably 
higher viability index, indicating the presence of more viable cells compared to necrotic cells. 
The same comparable in vivo results were observed in the lung cancer studies, whereby sc 
tumours of A549 cells mixed with BM-MSCs (2:1 ratio) were approximately 200mm3 larger 
than the cancer cell only control tumours. Ki67 staining also revealed an enhanced proliferative 
status of the BM-MSC + A549 tumours (Wang et al., 2016b). Although these co-injection 
models are not representative of real tumour development (discussed in section 1.4), it still 
highlights the possibility of how BM-MSCs can influence cell proliferation.  
Together these results suggest that BM-MSCs exert a pro-proliferative effect in multiple cancer 
types. An interesting observation was the differences in ratio of BM-MSCs mixed with cancer 
cells in these two in vivo studies. The breast cancer study used a higher number of BM-MSCs 
compared to cancer cells (60:40) and saw a profound increase in overall tumour size by 23 days 
post tumour implantation compared to control. However, the A549 tumours used half the 
number of BM-MSCs compared to cancer cells (1:2) and saw almost no difference in tumour 
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size at 23 days. It took 4 weeks for an observable difference to show between the 2 groups. This 
may suggest that the number of BM-MSCs present in the tumour stroma dictates the overall 
effect on cancer cell proliferation and that a higher number of BM-MSCs results in a stronger 
pro-proliferative effect. It also may indicate that not all cancer types respond as strongly to the 
pro-proliferative signalling provided by stromal BM-MSCs. 
1.2.2.2  Influence on Angiogenesis 
As tumours grow, blood vessels sprout to provide the tumour with a vasculature that enables 
the delivery of nutrients and removal of waste material. The growth of these tumour-associated 
blood vessels is known as angiogenesis. This process aids in increasing the malignancy of the 
tumour as it helps it grow larger and also supplies a vasculature which enhances the metastatic 
spread of disseminating tumour cells (Gupta et al., 2006; Hanahan et al., 2011)  
The influence of MSCs on angiogenesis has been widely studied due to the importance of vessel 
formation in wound healing, where MSCs play a critical role. Such studies show that MSCs 
enhance the formation of new blood vessels (Wu et al., 2007). Many in vivo studies look for 
signs of angiogenesis by staining for blood vessels in developed tumours that have been 
removed from the animal. Mandel et al. (2013) noted an increased neovascularization in the 
tumour capsule of the BM-MSC/MDA-MB-231 tumours, stained with hematoxylin/eosin, 
compared to control. Similarly, NMRI mice with pancreatic xenograft tumours had double the 
number of CD31+ vessels per mm2 in the BM-MSC injected group compared to the control 
group not injected with BM-MSCs (approximately 22 vs 11 CD31+ vessels per mm2, 
respectively) (Beckermann et al., 2008). CM from BM-MSCs has been found to contain high 
levels of vascular endothelial growth factor (VEGF). When this production of VEGF is silenced 
then the pro-angiogenic effect of the BM-MSCs is reversed and the CD31+ vessels per mm2 
consequently decrease (Beckermann et al., 2008).  
1.2.2.3 Influence on Metastasis 
Metastasis is the process whereby cells from the primary tumour disseminate, travel in the blood 
stream and take up residence in distant tissues creating metastatic lesions. Common sites of 
metastatic lesions vary by tumour type but include the brain, bone marrow, lymph nodes, liver 
and lungs (Gupta et al., 2006). From the research so far the influence of MSCs on cancer cell 
metastatic properties is also cancer type or model specific. A greater number of metastatic 
lesions in the liver resulted when MSCs and the colon cancer cell line KM12SM were co-
injected into nude mice (2.6 ± 4.3 in control versus 15.1 ± 6.0 in the co-mixed animals). 
Conversely, the motility of the lung cancer cell line A549 was significantly inhibited when 
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treated with MSC CM in vitro (p < 0.01). Even within the same cancer type the metastatic 
effects of MSCs are not consistent. In one instance the migration of the MDA-MB-231 cell line 
was significantly reduced when treated with MSC CM (p < 0.001) (Clarke et al., 2015). In 
contrast, in another study using the same cell line the opposite was concluded, where MDA-
MB-231 cell migration significantly increased by approximately 25% when treated with MSC 
CM (p < 0.001) (Dittmer et al., 2009). Both these studies also used the same model of cellular 
migration. This difference could be an example of a bigger issue that exists involving the 
heterogeneity between the same cancer cell line amongst different research groups (Klotz et al., 
1995). This problem does make it difficult to understand clearly the influence of MSCs on 
metastasis. However, metastasis is a complex and multistage process that requires more than 
one experiment to assess.  
Adhesion, a process important in a cells ability to metastasise, of cancer cells has also been 
shown to be influenced by MSCs (El-Haibi et al., 2012; Gonzalez et al., 2017; Gupta et al., 
2006). MSCs co-cultured with both MDA-MB-231 or MCF-7 breast cancer cell lines, 
significantly increased the expression of lysyl oxidase (LOX) (p < 0.01) and discoidin domain 
receptor 2 (DDR2) (p < 0.05) in both cell lines (El-Haibi et al., 2012; Gonzalez et al., 2017). 
LOX and DDR2 are important for cancer cell adhesion to fibronectin and collagen I, 
respectively. By increasing the expression of LOX and DDR2, MSCs enable cancer cells to 
more readily migrate from the primary tumour site.  
1.3 Breast Cancer Metastasis and its Measurement 
Approximately 600 woman die from metastatic breast cancer per year in New Zealand (BCF, 
2017). The development of secondary tumour lesions, via metastasis, is the leading cause of all 
cancer related deaths. Studies suggest that up to 90% of patients die due to the development of 
metastasis which underlies the need to understand this process in more depth (Gupta et al., 
2006). In doing so, additional targets can be identified for cancer therapy advancement. And 
with ever increasing numbers of breast cancer diagnoses in NZ (3000+/year), it would appear 
the demand for such interventions is critical (BCF, 2017).  
Metastasis is a multistage process that starts with the dissemination of cancer cells from the 
primary tumour and ends with the development of secondary tumours at distant sites around 
the body. The cellular events that lead to the metastatic spread of the primary tumour can be 
assessed using in vitro techniques. Because of this, the question of how certain stimuli alter 
breast cancer metastasis can be dissected in a detailed way to help pinpoint which cellular 
events are specifically altered. The main cellular events of metastasis that are regularly assessed 
7 
 
are the acquisition of an invasive phenotype, increased cell motility, attachment and movement 
along structural proteins, and invasion (Gupta et al., 2006). 
First in the process of metastasis, the cancer cell must acquire an invasive phenotype. This is 
achieved via genetic changes that alter cell to cell adhesions and cell polarity (Gupta et al., 
2006). Experimentally these changes can be detected in vitro by western blot and microscopy 
techniques (Dittmer et al., 2009; Shin et al., 2010). Genetic markers assessed via western blot 
include E-cadherin (loss of indicates disrupted cell-cell adhesion), vimentin and snail (increased 
expression of both indicates a change from epithelial to mesenchymal polarity) (Dittmer et al., 
2009). Microscopy techniques can assess the polarity of the cell either with simple light 
microscopy to look at cell morphology or with fluorescent markers such as rhodamine-
phalloidin (visualises actin rearrangement/polymerization) (Dittmer et al., 2009; Shin et al., 
2010).   
After these phenotypic changes, the cell can disseminate from the primary tumour. This requires 
the cell to be motile (Gupta et al., 2006). The motility of a cell can be assessed in vitro by 
several different assays. The most common are the Boyden chamber migration assay or the 
wound healing/scratch assay (Hague et al., 2008). The Boyden chamber assay is a 3-
dimensional (3D) model that quantifies how many cells (by cell count or colourimetric assay) 
move through a porous membrane from an upper chamber to a lower chamber. The scratch 
assay is a 2-dimensional model that monitors the movement of cells across an artificial wound 
or scratch using a microscope. From this cell morphology can be visualised as well as the degree 
to which the wound is closed by migrating cells.  
The migrating cell will adhere to and move along structural fibres within the ECM to achieve 
directional migration. Prominent ECM components involved in breast cancer metastasis include 
collagen, fibronectin, laminin and tenascin (Gould et al., 1990; Ioachim et al., 2002). Cell 
adhesion assays can reveal which interactions with which fibres may be influenced by a 
treatment. Cells are plated on top of a collagen (as an example) coated well plate and then 
washed off after an incubation phase. The number of remaining cells adhered to the collagen 
can then be analysed (Humphries, 2001).  
Following migration, the cell will then need to traverse the basement membrane surrounding 
the local blood vessels. To do so, it secretes proteases such as MMPs which cleave and 
breakdown the various components of the basement membrane (Gupta et al., 2006). To assess 
this phase of metastasis, an altered version of the previously described Boyden chamber model 
is used. A layer of Matrigel is added to the upper chamber which mimics the presence of the 
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dense basement membrane (Hague et al., 2008). The cells are then plated on top of this and the 
number of cells able to invade through the Matrigel layer and porous membrane to the lower 
chamber are quantified. In this way, the cells’ invasive capability is assessed.  
Once these metastatic cells have disseminated into the blood stream the migrating cells travel 
to distant sites and form secondary tumours. In vivo models focus on the presence or absence 
of these secondary tumours rather than the cellular events that precede them. The downside to 
this is a lack of knowledge as to how the metastatic change occurred. The question of what 
stage or process of metastasis was influenced goes unanswered. This is where the in vitro 
techniques discussed can complement the in vivo studies. 
1.4 MSCs and Breast Cancer Metastasis 
BM-MSCs have been shown to directly influence the metastatic capabilities of breast cancer 
cells in a number of studies (Karnoub et al., 2007; Albarenque et al., 2011; Meleshina et al., 
2015). Despite these studies, the defining role of MSCs in breast cancer metastasis is still 
unresolved, as the results between seemingly similar in vivo studies show opposite effects. 
Karnoub et al. (2007) developed xenograft models of breast cancer using a number of different 
breast cancer cell lines: MDA-MB-231, MCF-7, MDA-MB-435 and HMLER. These were 
either injected into the animals alone or mixed with BM-MSCs at a ratio of 1:3 BC cells:MSCs. 
In all groups there was a significant increase in the metastatic index of the mice co-injected 
with MSCs compared to those only injected with breast cancer cells (p < 0.05). A point of 
interest was the development of metastatic lung nodules. When compared to a study by 
Meleshina et al. (2015), the presence of metastatic lung nodules in breast cancer tumour bearing 
mice differ. Karnoub et al. (2007) reported an increase in metastatic lung nodules up to 
sevenfold higher in the breast cancer-MSC groups when compared to breast cancer cell only 
groups, whereas Meleshina et al. (2015) reported there were ‘significantly fewer’ animals with 
lung nodules when exposed to BM-MSCs, with only 1/4 animals developing metastases 
compared to 4/5 in the MDA-MB-231 cell line-only group. However, when the differences 
between experimental technique are broken down these two studies differ in important aspects, 
the time of MSC injection and the ratio of MSC to breast cancer cells. This compounds the 
difficulties in MSC research, as discussed previously, of heterogeneous MSC populations. 
Additional to that, how MSCs influence metastasis is not investigated in a defined way, as can 
be seen in the differences existing between the current studies. Because of this a clear answer 
to the question of ‘How do MSCs influence breast cancer metastasis?’ is hard to obtain.  
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Further in vivo work appears to agree with the conclusion reached by Karnoub et al. (2007). 
Albarenque et al. (2011) used the same breast cancer cell line (MDA-MB-231) that Karnoub et 
al. (2007) and Meleshina et al. (2015) had shown differing results for and concluded that BM-
MSCs increased the metastatic burden of animals.  
There is therefore some disagreement on the overall influence of MSCs on breast cancer 
metastasis at this stage. But if the methodology of each study is compared with what is known 
about the basic pathological stages of metastasis and breast cancer exposure to MSCs, then a 
better grasp of what results to assign more validity to can be reached. While the methodology 
used by Karnoub et al. (2007) aligns better to the way interactions between MSCs and breast 
cancer are studied in vitro (co-culture models such as Boyden chambers), the approach 
Meleshina et al. (2015) and Albarenque et al. (2011) took better reflects the delay between 
tumour development and the migration of MSCs. In fact, Albarenque et al. (2011) was the only 
study that used a model that demonstrated the development of a primary tumour first (palpable 
subcutaneous tumour) followed by the intravenous injection of MSCs, which follows the co-
development process best, since the developing tumour is needed to attract these cells to the 
tumour stroma, in order to have an effect on primary tumour metastasis. Given this was the best 
representative model of the influence of MSCs on primary tumour metastasis, it could be argued 
that the results are more valid in terms of clinical relevance. Based on this in vivo evidence, it 
could be concluded that MSCs enhance the metastatic spread of primary breast tumours.  
This conclusion can only be made for triple negative breast cancer cell lines as all but one of 
the aforementioned in vivo studies focused on the triple negative breast cancer cell line, MDA-
MB-231. Karnoub et al. (2007) found that the metastatic index of both oestrogen receptor 
positive (MCF-7) and triple negative (MDA-MB-231) breast cancer cell lines significantly 
increased (p < 0.05). However, further investigations into breast cancer metastasis within that 
study focused only on the MDA-MB-231 cell line. This was due to the decision that the increase 
in the metastatic index of MCF-7 cells was due to the concomitant effect on cell proliferation 
and not cell motility/metastatic cellular events. 
1.5 Aim and Hypothesis 
The aim of this study was to use CM from MSCs to assess, in vitro, the influence of BM-MSCs 
on the metastatic cellular events of the breast cancer cell lines MDA-MB-231 and MCF-7. With 
the use of in vitro techniques (as outlined in section 1.3), further insight into which metastatic 
cellular events BM-MSCs influence, in order to alter breast cancer cell metastasis as seen in in 
vivo studies, can be defined. The rationale behind using BM-MSC CM was to consider the 
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combined efforts of the complete secretome produced by MSCs. CM generated by exposure of 
the media to MSCs for one or five days was used to see whether longer exposure to the MSC 
secretome would produce differing responses. It is hypothesised that the breast cancer cells will 
respond differently from control conditions when exposed to MSC CM. However, current 
literature remains inconclusive as to whether the metastatic processes assessed will be enhanced 
or inhibited. Specific aims are as follows: 
• Develop an appropriate method for the production of MSC CM. 
• Assess the validity of the migration models by first assessing cell viability. 
• Perform experiments to evaluate metastatic cellular events: migration, invasion and 
adhesion. 
• Assess the validity of using healthy MSCs in culture as a model of the MSCs present in 















Chapter 2. Materials and Methods 
2.1 Materials 
The cell lines used were the triple negative breast cancer cell line MDA-MB-231 ,oestrogen 
receptor (ER) positive breast cancer cell line MCF-7, the human bone marrow MSC line 
RCB2157 and a human fibroblast cell line kindly donated by Hayley Nehoff of the Griesh lab 
group (cell line unknown). All cancer cell lines were used from passage 1 to 35. MSCs from 
passage 1 to 10. Cell culture reagents were Dulbecco's Modified Eagle's Medium (DMEM) 
used serum free with 100 units/mL penicillin and 100 µg/mL streptomycin or supplemented 
with 5% or 10% fetal bovine serum (FBS), Phosphate buffered saline (PBS) and Trypsin (All 
sourced from Gibco). MTT Assay reagents were MTT (Global Science) and DMSO (Sharlau). 
MTT was dissolved in PBS to create a stock solution of 5 mg/ml. Collagen I was diluted with 
PBS into a 5 mg/ml stock solution for use in migration and invasion assays (Corning). Matrigel 
was not diluted for invasion assays (Corning). Fibronectin for adhesion assays was diluted with 
PBS into a 5 mg/ml stock solution (Gibco).  
2.2 Cell Culture and Maintenance  
Cells were incubated at 37oC in 5% CO2 humidified conditions and maintained in DMEM 
supplemented with either 10% or 5% FBS, 100 units/mL penicillin and 100 µg/mL 
streptomycin. Cells were grown to approximately 70% confluency in 75 cm2 culture flasks 
before passaging.  
For passaging, media was discarded and cells washed once with warm PBS. Two ml of trypsin 
was then added and the flask incubated for 3-5 minutes. Following incubation, a Nikon 
microscope was used to visually determine that the cells were no longer adhered to the flask. 
Once detached, 2 ml of fresh media was added to the trypsin-cell solution to deactivate the 
trypsin. This solution was then centrifuged at 1500 rpm for 3 minutes at 4oC using the 
Eppendorf Centrifuge 5810 R. The supernatant was discarded and the cell pellet re-suspended 
in 10 ml of fresh media. For experiments, cells were then counted using a haemocytometer to 
determine cell number per ml of media (method adapted from Abcam, 2017). From this the cell 
numbers required for plating experiments were calculated.  
2.3 MSC Conditioned Media Generation 
Protocol 1- MSCs were grown to confluency in 175 cm3 flasks and then incubated for 1 or 5 
days in 10 ml of serum free DMEM. Following incubation, the media was collected and 
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centrifuged at 4000 rpm for 8 minutes using the Eppendorf Centrifuge 5810 R. This was then 
labelled as either 1 or 5 day MSC-CM and stored at -80oC until needed.  
Protocol 2- 9 × 105 MSCs were seeded into a 175 cm3 flask and allowed to adhere overnight. 
Media was then replaced with 10 ml of serum free DMEM. Following incubation, the media 
was collected and centrifuged at 4000 rpm for 8 minutes using the Eppendorf Centrifuge 5810 
R. This was then labelled as either 1 or 5-Day MSC-CM and stored at -80oC until needed. 
Protocol 2 was the one utilised for all experiments in our study. Fibroblast CM was generated 
in the same way except where cell number seeded was 1 × 106. 
2.4 MTT Assay 
Briefly, the MTT assay works through NADPH-dependent enzymes and mitochondrial 
dehydrogenase reducing yellow MTT to purple formazan crystals. These enzymes are only 
active in viable cells therefore, the production of formazan crystals corresponds to the number 
of viable cells (Mosmann, 1983; Berridge et al., 1996). In this study the MTT assay was used 
to assess cell viability, migration, invasion and adhesion. 
Following various experimental incubations, MTT (5 mg/mL) was added to each well to 
achieve a final concentration of 0.5 mg/ml. Culture plates were then incubated for 3 hours after 
which media-MTT solution was removed and formed formazan crystals dissolved in 200 μl of 
DMSO. Absorbance was then read at 560 nm using the Bio-Rad Benchmark Plus Microplate 
Spectrophotometer©. 
2.5 Cell Viability  
MDA-MB-231 or MCF-7 breast cancer cells were seeded at a density of 5 × 103 in 96 well 
plates and allowed to adhere for 24 hours. Media was then removed and cells washed gently 
once with warm PBS. One hundred μl of 10% media, serum free media, 1-Day CM or 5-day 
CM was added to each well. Cells were then incubated for 0, 24, 48 or 72 hours after which an 
MTT assay was used to assess cell viability (see section 2.3). All conditions were done in 
triplicate and repeated at least 3 times.  
2.6 Wound Healing Scratch Assay 
MDA-MB-231 cancer cells were plated at a density of 3 × 105 in 6 well plates and left to grow 
until approximately 90% confluent. A 200 µl pipette tip was used to scratch a straight line 
through the centre of each well creating a ‘wound’ for the cancer cells to migrate across over a 
period of 20 hours. Beyond 20 hours the cells may begin to proliferate, detach and re-adhere in 
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the ‘wound’ therefore impairing the results and increasing the likelihood of a false result. Media 
was then removed and cells washed gently once with warm PBS. Following this, 1000 μl of 
serum free DMEM, 1-Day CM or 5-Day CM was added to each well. Photos pre and post the 
20 hour incubation were taken with a Nikon microscope.  
2.7 Cell Migration and Invasion 
The Boyden chamber model was used in this study to assess both migration and invasion (Fig. 
2). First the undersides of the insert membranes were coated with 5 μg/ml collagen I (Clarke et 
al., 2015). For invasion assays, the upper side was additionally coated in 35μl of Matrigel™. 
In the bottom chamber was 600μl of either serum free media, 1-Day CM, 5-Day CM or 5 × 104 
MSCs in 600μl of serum free media. In the upper chamber, 5 × 104 of either MDA-MB-231s or 




Figure 2. Schematic of the Boyden chamber setup for both migration and invasion studies. 
After incubation, MTT was added to the bottom well and incubated for a further 3 hours. 
Following this, media from the bottom wells was removed via aspiration and the top wells were 
cleaned out with a cotton tip. Inserts were then placed in fresh 24 well plates containing 120μl 
of DMSO. This enabled the formazan crystals, formed by cancer cells which migrated through 
the membrane, to be dissolved. One hundred μl of each sample was transferred into a 96-well 
Upper Chamber 








plate well. Absorbance was then read at 560 nm using the Bio-Rad Benchmark Plus Microplate 
Spectrophotometer©.  
2.8 Cell Adhesion 
Ninety six-well plate wells were coated with 5 μg/ml collagen or fibronectin. Four × 103 MDA-
MB-231 or MCF-7s were then seeded into each well suspended in 100 μl of either serum free 
media, 10% FBS media, 1-Day CM or 5-Day CM. Uncoated wells were also seeded in the same 
manner as a control. Seeded plates were then incubated for 30 mins after which media was 
aspirated and replaced with media containing MTT (5 μg/ml) (See section 2.3 for details).  
2.9 Generation of Activated MSCs 
1. Cancer cell CM generation - MDA-MB-231 or MCF-7 cells were seeded in 10 mL 5% 
DMEM at a density of 9 × 106 in a 75cm2 flask and left to adhere overnight. Media was then 
removed and replaced with serum free DMEM. The cells were then incubated for a further 48 
hours. Following this, the newly generated CM was collected and spun at 4000 rpm for 8 
minutes.  
2. MSC Activation - MSCs were seeded in 10% DMEM at a density of 9 × 105 in a 75cm2 flask 
and left to adhere overnight. The media was then removed and replaced with a 10 ml 1:1 mixture 
of serum free DMEM and freshly generated cancer cell CM from either MDA-MB-231 or 
MCF-7 cells. MSCs were then incubated for a further 48 hours. These cells were termed 
‘activated’ (actMSCs). Those activated with either MDA-MB-231 or MCF-7 CM were used in 
migration assays with the corresponding breast cancer cell line.  
3. Migration Assay - See section 2.6 for assay details. Two different set ups of the migration 
assay were run with the actMSCs.  
Breast Cancer Cell Migration- Either MDA-MB-231 or MCF-7 cells were seeded in the 
upper chamber at a density of 5 × 104 in serum free DMEM. The corresponding actMSCs 
were then seeded in the bottom chamber at a density of 5 × 104 in serum free DMEM. 
Control was normal inactivated MSCs (nMSCs) in the bottom chamber and either MDA-
MB-231 or MCF-7 cells in the upper chamber, seeded in that same manner. 
MSC Migration- Either nMSCs (control), MDA-MB-231 actMSCs or MCF-7 actMSCs 
were seeded in the upper chamber at a density of 5 × 104 in serum free DMEM. The 
bottom chamber contained 600 μl of serum free DMEM.  
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2.10 Statistical Analysis 
All data was analysed using GraphPad Prism 6 software. All data analysed were considered 
statistically significant at p < 0.05. Where there were only 2 sample groups a 2-tailed unpaired 
Students t-test was used to analyse the data sets. Two-tailed was selected to avoid the 
presumption of which direction the data would move in. For data sets containing 3 or more 
sample groups, data were analysed using a one-way analysis of variance (ANOVA) coupled 
with a Dunnets post-hoc test. This is preferred to individual t-tests as it divides the type one 
error rate of 0.05 between the total number of sample groups within a data set. Running 
individual t-tests would increase the risk of a type one error occurring. A Dunnets post-hoc test 
was selected as the comparisons wanted were changes in treatment groups relative to control 
and not between treatment groups. For data sets with 2 factors (proliferation and adhesion), a 
2-way ANOVA was used coupled to a Bonferonni post hoc test. All assumptions of the selected 
parametric statistical tests were presumed to be met. All data were transformed from absorbance 
to percentage of control before analysis. All experiments were performed at least 3 times in 
triplicate with the exception of the activated MSC experiments which were only repeated 2 
times.  




Chapter 3. Results 
3.1 Conditioned Media Does Not Influence Breast Cancer Cell Viability  
Great care was taken when developing a method for the generation of the MSC CM. The 
literature suggested that simply growing the MSCs to an approximate confluency and then 
culturing in serum free media for the desired length was sufficient for generating CM (See 
Protocol 1 in chapter 2.2) (Lin et al., 2008; Goldstein et al., 2010; Meleshina et al., 2015). 
However, initial studies using this method produced inconsistent results with high error 
margins. Due to this, a more appropriate method had to be developed that allowed for better 
control of the CM, seeding an exact number of MSCs rather than just estimating confluency 
(See Protocol 2 in chapter 2.2). It was this method that was used for the remainder of this study. 
The margins of error could be tighter however, although not published in any literature, 
discussion with fellow researchers in this field revealed that this limitation is known and 
accepted as what the cells secrete cannot be completely controlled for between batches of CM.  
3.1.1 Mesenchymal Stem Cell Conditioned Media 
In order to determine the validity of the use of CM in our study, breast cancer cell viability was 
assessed. The main purpose of assessing the influence of MSC CM on breast cancer cell 
viability was to ascertain whether CM altered cell proliferation in any way. This in turn helps 
determine the validity of the Boyden Chamber migration models. Both MDA-MB-231 (Fig. 
3A) and MCF-7 (Fig. 3B) cells were exposed to MSC CM for up to 72 hours. 1- Day CM and 
5- Day CM elicited no statistically significant changes in either cell line, with one exception in 
the MDA-MB-231 cells exposed to 5- Day CM for 72 hours. Cell viability significantly 
increased to 164.9 ± 24.7% of 0% DMEM control (p ≤ 0.01; Fig 3A). Time did not significantly 
alter the effect of MSC CM either. From this, the results of the migration assays could now be 
interpreted as changes in cell migration and not just enhanced cell proliferation.  
3.1.2 Fibroblast Conditioned Media 
Fibroblasts were used to generate a control cell line CM. This helped determine whether the 
effects of the MSC CM on cell viability were cell type specific or not. Both breast cancer cell 
lines were plated and treated in the same way as during the MSC CM cell viability experiments 
whereby cells were exposed to fibroblast CM for up to 72 hours. Similar to the MSC CM, only 
minor fluctuations from control were observed with Fibroblast CM, none of which exerted a 





























Figure 3. Viability of either A) MDA-MB-231 or B) MCF-7 cells treated with BM-MSC CM.  
Cells were seeded at 5 × 103 cells per well and treated with 100 μl of either 1-Day CM or 5-
Day CM. Following treatment, cell viability was analysed via MTT assay. Data was analysed 
using a two-way ANOVA coupled to a Bonferroni post-hoc test. ** Denotes a statistically 
significant change compared to untreated control within the same time point, p ≤ 0.01. Data 
points express mean ± SEM. n = 3 independent experiments.
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Figure 4. Viability of either A) MDA-MB-231 or B) MCF-7 cells treated with Fibroblast CM. 
Cells were seeded at 5 × 103 cells per well and treated with 100 μl of either 1-Day CM or 5-
Day CM. Following treatment, cell viability was analysed via MTT assay. Data was analysed 
using a two-way ANOVA coupled to a Bonferroni post-hoc test. No statistical significance 
found. Data points express mean ± SEM. n = 3 independent experiments. 
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3.2 Breast Cancer Cell Migration  
3.2.1 Boyden Chamber Model 
The Boyden chamber model was used to assess the influence MSC CM has on breast cancer 
cell migration in a 3D model. Breast cancer cells were exposed to both MSC CM and actual 
MSCs (50000 MSCs) to see whether there was a difference in response between MSC secreted 
factors and the actual presence of the cells. Both MDA-MB-231 and MCF-7 cells showed an 
increased migration capacity when exposed to all experimental conditions when compared to 
serum free control (0% DMEM) (Fig. 5).  
MSC CM increased MDA-MB-231 migration to a higher degree (around 28% more) than the 
presence of actual MSCs although both were statistically significant (Fig. 5A). MSCs 
significantly increased MDA-MB-231 migration to 117.9 ± 0.01% of control (p = 0.016). 
However, MSC CM significantly increased migration to 144.8 ± 2.9% (p = 0.0005) and 180 ± 
4.0% (p < 0.0001) of control when exposed to 1-Day or 5-Day CM, respectively.  
In the MCF-7 cell line, the opposite effect was observed whereby the most noticeable increase 
in migration was in the cells exposed to MSCs not CM (Fig. 5B). The migration capacity of 
MCF-7 cells exposed to MSCs significantly increased, doubling to 208.3 ± 33.7% of control (p 
= 0.0061). A slight increase in MCF-7 cell migration was observed when exposed to MSC CM, 
although no results were statistically significant. One-Day CM and 5-Day CM increased 
migration to 126.0 ± 5.6% and 145.0 ± 7.8% of control, respectively.  
3.2.2 Scratch Assay Model 
The scratch assay model was used to assess cell migration in a 2D system (Fig. 6). However, 
due to the clustering of MCF-7 cells grown in culture it was not possible to undertake this assay 
using that cell line. Only MDA-MB-231 were able to be analysed in this system as a result.  
No quantitative data was collected from this assay however assessment of the wound edge and 
the cells occupying the gap give some information on migration capacity. As seen in Figure 6, 
the degree of cell coverage in the gap is enhanced in the cells treated with either 1-Day or 5-
Day CM compared to control. Additionally, the cells’ morphology appears to be more 
profoundly elongated compared to control cell after 20 hours. This is the most notable in the 
cells treated with 5-Day CM (examples indicated by arrows). These observations match up with 
those seen in the 3D Boyden chamber model whereby the greatest increase in migration 



























Figure 5. Migration of either A) MDA-MB-231 or B) MCF-7 cells exposed to various 
conditions in the bottom well of a Boyden chamber set up. Breast cancer cells were seeded at 5 
× 104 in the upper chamber and incubated for 48 hours to allow for migration through to the 
underside of the membrane in the bottom chamber. The number of migrated cells was analysed 
via MTT assay. Data was analysed using a one-way ANOVA coupled to a Dunnets post hoc 
test. * Denotes a statistically significant change compared to 0% DMEM control. * p ≤ 0.05, ** 



















































Figure 6. Migration of MDA-MB-231 cells in a wound healing model. MDA-MB-231 cells 
were seeded at a density of 3 × 10
5
 and a scratch created. Cells were then treated with 1 ml of 
either 0% DMEM, 1-Day CM or 5-Day CM and left for 20 hours to migrate across the gap. 




3.3 Breast Cancer Cell Invasion 
The Boyden chamber model was also used to assess cell invasion in both the breast cancer cell 
lines (Fig. 7). Unlike the migration studies, no statistically significant results were observed. 
Definite trends were seen in the MDA-MB-231 cells (Fig. 7A). Relative to the serum free 
DMEM control group, all treatment groups can be seen to increase the percentage of invaded 
cells. The highest increase of 413.3 ± 140.0% was seen in the MDA-MB-231 cells exposed to 
MSCs. Of note is the large variance (SEM = 140.0%). This same degree of variance was 
observed in all the MDA-MB-231 treatment groups, with 1-Day and 5-Day CM having SEMs 
of 47.3% and 172.7%, respectively. This effected the overall trend observed and certainly lead 
to the lack of statistical relevance in any of the MDA-MB-231 data. 
No notable changes were found in any of the MCF-7 treatment groups when compared to the 
serum free DMEM control group, with the invasion capacity of MCF-7 cells remaining 









































Figure 7. Invasion of either A) MDA-MB-231 or B) MCF-7 cells exposed to various conditions 
in the bottom well of a Boyden chamber set up. Breast cancer cells were seeded at 5 × 10
4 
in 
the upper chamber and incubated for 72 hours to allow for invasion through the Matrigel layer 
to the underside of the membrane in the bottom chamber. The number of migrated cells were 
analysed via MTT assay. Data was analysed using a one-way ANOVA coupled to a Dunnets 






3.4 Cell Adhesion  
Cell adhesion was assessed using two different structural proteins (Collagen I and Fibronectin) 
commonly found in the tumour microenvironment and the surrounding ECM of healthy tissue, 
both known to be used by breast cancer cells to migrate (Insua-Rodríguez et al., 2016). 
Uncoated wells were used as a control to make sure the cells were noticeably adhering to the 
structural proteins and to validate any effects observed. 
3.4.1 Collagen I 
No significant alteration in adherence to collagen I was obtained in this experiment with either 
cell line both between uncoated and coated within the same treatment or when comparing serum 
free DMEM coated control to the coated treated groups (Fig. 8). 
3.4.2 Fibronectin 
When uncoated controls were compared with the coated counterparts no statistically significant 
observations were observed in either cell line (Fig. 9). However, MSC CM did result in a 
statistically significant increase in adherence to fibronectin in the MCF-7 cell line (Fig. 9B). 
When compared to serum free DMEM coated control, both 1-Day and 5-Day CM increased 
cell adherence from 53.8 ± 5.8% to 112.4 ± 18.4% and 104.2 ± 7.6% of control, respectively (p 
= 0.013 and p = 0.038, respectively). No changes in cell adherence to fibronectin were observed 









































Figure 8- Adhesion of either A) MDA-MB-231 or B) MCF-7 cells to collagen I. Cells were 
suspended in either 0% DMEM, 1-Day CM or 5-Day CM and seeded at a density of 4 × 103 in 
collagen I coated (5µg/ml) or uncoated wells. Following a 30 minute incubation, adhered cells 
were analysed via MTT assay. Data was analysed with a two-way ANOVA coupled to a 




























Figure 9- Adhesion of either A) MDA-MB-231 or B) MCF-7 cells to fibronectin. Cells were 
suspended in either 0% DMEM, 1-Day CM or 5-Day CM and seeded at a density of 4 × 103 in 
fibronectin coated (5µg/ml) or uncoated wells. Following a 30 minute incubation, adhered cells 
were analysed via MTT assay. Data was analysed with a two-way ANOVA coupled to a 
Bonferroni post-hoc test. * Denotes a statistically significant change compared to 0% DMEM 
coated control. * p < 0.05. Data points express mean ± SEM. n = 3 independent experiments. 
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3.5 Activated MSCs 
The Boyden chamber model was used to assess the effect of exposing MSCs to cancer cell CM 
and how this altered the effect these MSCs had on cancer cell migration. This was done to 
assess the validity of the method used in our study in relation to how MSCs would behave in 
the tumour microenvironment once exposed to the cancer cells.  
3.5.1 Cancer Cell Migration 
When compared to normal MSCs (nMSC), activated MSCs (aMSCs) enhanced the migration 
capability of both MDA-MB-231 and MCF-7 cell lines (Fig. 10). The MCF-7 cell line 
responded the most to actMSCs, with the percentage of migrated cells increasing to 189.5 ± 
20.0% of control, compared to the control group of MCF-7 cells exposed to nMSCs (p = 0.047). 
The migration of MDA-MB-231 cells also significantly increased (112.8 ± 0.4% of control, p 
= 0.0013) compared to the MDA-MB-231 cells exposed to nMSCs. This indicates that MSCs 
in the tumour microenvironment are likely to behave differently than those not previously 
exposed to cancer cells, such as those in cell culture. 
3.5.2 MSC Migration 
The migration capacity of the actMSCs was also assessed to see if the properties of the cells 
themselves were altered (Fig. 11). When exposed to cancer cell CM from either the MDA-MB-
231 or the MCF-7 cell line, the migration capacity of MSCs greatly increased compared to the 
nMSC control group (205.0 ± 44.3% and 278.8 ± 26.2% of control, respectively). Due to the 
low n numbers for this particular experiment, the statistical significance was unreliable when 
analysing the results. However, the MCF7-actMSC group did significantly increase with a p 




































Figure 10- Migration of MDA-MB-231 or MCF-7 cells in the presence of normal MSCs or 
activated MSCs. MSCs were seeded at a density of 3 × 104 in the lower chamber and breast 
cancer cells were seeded at a density of 5 × 104 in the upper chamber. This system was incubated 
for 48 hours to allow for migration of breast cancer cells to the underside of the membrane in 
the bottom chamber. The number of migrated cells was assessed via MTT assay. Data was 
analysed using an unpaired t-test. * Denotes a statistically significant change compared to 
normal MSC control group. * p ≤ 0.05. ** p ≤ 0.01. Data points express mean ± SEM. n = 2 



















Figure 11. Migration of activated MSCs compared to normal MSCs. MSCs were seeded at 
5 × 104 in the upper chamber and incubated for 48 hours to allow for migration through to 
the underside of the membrane in the bottom chamber which contained 600 µl of 0% DMEM. 
The number of migrated cells was analysed via MTT assay. Data was analysed using a one-
way ANOVA coupled to a Dunnets post hoc test. * Denotes a statistically significant change 





Chapter 4. Discussion 
The overall aim of this project was to observe how BM-MSC CM affected the in vitro metastatic 
properties of breast cancer and whether these effects differed between different subtypes of 
breast cancer. The triple negative cell line, MDA-MB-231, and the ER+ cell line, MCF-7, were 
used to assess this subtype comparison.  
Few studies have focused on the effects of BM-MSC CM in vitro on cancer cell properties, 
opting instead to focus on co-culture models. Because of this, few studies exist that assess the 
influence of the complete soluble factor profile produced by MSCs in the CM. Most simply 
screen for which factors were highly expressed by the MSCs and then go about exposing the 
cancer cells to these factors individually to ascertain the influence of each one separately. The 
heavily cited study by Karnoub et al. (2007) is an example of this approach whereby MDA-
MB-231 breast cancer cells and MSCs were co-cultured and a cytokine array was used to detect 
which cytokines were elevated. The elevated cytokine, CCL5, then became the focus rather 
than the MSCs themselves. Though this is a completely valid method for ascertaining potential 
therapeutic targets and for uncovering the components of MSC CM, focusing on one factor at 
a time fails to assess the combined efforts of the complete secretome profile produced by the 
MSCs. As a tumour would be exposed to the entire profile, the use of CM is an excellent way 
to assess the impact of this. This then gives a better understanding of the pathology behind the 
tumour and its microenvironment as a whole network, something this study hopes to achieve.  
It is clear that the effect on cell viability or proliferation is not often taken into account before 
undertaking experiments that look at changes in metastasis. Because of this it is not known if 
the observed alterations in any given in vitro metastatic model are caused by alterations in a 
cell’s ability to migrate or simply whether the proliferation status of the cell population is 
altered giving a false outcome. Therefore, the first part of the experimental process was to 
validate the migration model being used. In this study the Boyden chamber model was selected 
and the MTT assay was used to assess cell migration through the porous membrane. However, 
it needed to be made clear that any observation in this model was due to cell migration and not 
just an increase in cell viability. It was confirmed that all experimental conditions that were to 
be used in the Boyden chamber model did not significantly affect cell viability of either cell 
line compared to serum free DMEM control (Fig. 3). With this confirmed, any significant 
deviation from control in the migration assay will be evidence of cell migration not simply an 
alteration in cell viability. The only point in which a statistically significant increase in cell 
viability, compared to serum free DMEM, was observed, was in the MDA-MB-231 5-Day CM 
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treated group at 72 hours (p < 0.01) (Fig. 3A). However, this does not affect the migration assay 
as the assay is run for 48 hours and at that time point cell viability was not significantly altered. 
A study by Karnoub et al. (2007) made this same distinction when looking at the possible 
metastatic influence of MSCs on breast cancer cell lines. The authors commented that those 
cell lines whose growth kinetics were heavily altered by the presence of MSCs were not suitable 
for metastatic evaluation as it would be unclear whether that was having a simultaneous 
influence on the results. 
Interestingly, it has been observed in other studies that MDA-MB-231 cell viability 
significantly decreases when exposed to BM-MSC CM. Meleshina et al. (2015) cultured MDA-
MB-231 cells in BM-MSC CM for 48 hours and recorded a significant decrease in cell viability 
as accessed by the MTT assay (p < 0.05). However, the conditions of this experiment were 
rather different to that of this study. The first notable difference was the CM the cells were 
exposed to was mixed with fresh media containing 10% FBS at a 1:1 ratio. This would dilute 
the concentration of the secretome profile in the CM whereas our study did not do this. 
Additionally, it was not stated how the CM was generated. Lastly, our study did not use FBS 
in the CM or the control group as Meleshina et al. (2015) did. This was to avoid the FBS 
potentially influencing both the viability of the cells and the components of the CM. With these 
differences considered, the results of the 1- Day and 5-Day BM-MSC CM in this study and the 
work conducted by Meleshina et al. (2015) cannot be directly compared. The experimental 
differences between the two studies may account for the variance in results. Meleshina et al. 
(2015) did claim that the cell growth inhibition they observed must be due to the soluble factors 
produced by the BM-MSCs, although these factors were diluted by the addition of fresh media. 
Perhaps this data when compared to ours suggests a concentration dependent effect of BM-
MSC CM. Future investigations into the effect of BM-MSC CM on cell viability could include 
a dilution factor series to confirm this.  
Despite there being no significant alteration in MCF-7 cell viability in this study, other research 
has shown otherwise (Fig. 3B). Rhodes et al. (2010) found that the proliferation status of MCF-
7 cells treated with 1-Day BM-MSC CM significantly increased by 14.34 ± 3.09% compared 
to control (p < 0.01). However, similar to the comparative studies for MDA-MB-231 cell 
viability, there are crucial differences between the experimental methods. This time it was the 
control conditions, which used MCF-7 CM in which to culture the control MCF-7 cells. If the 
same control conditions were selected in both these studies, then perhaps the same experimental 
outcome would have occurred. 
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Other studies have found varying effects of MSC CM on cancer cell viability or proliferation. 
For example, the viability of the lung cancer cell lines H1299, H460 and A549 was significantly 
decreased by around 50% when exposed to BM-MSC CM for 72 hours (p < 0.01) (Attar-
Schneider et al., 2016). Conversely, when the colon cancer cell line, KM12SM, was exposed 
to MSC-CM no change in cell number was observed when compared to control media. This 
was observed throughout the 7 days that the cells were exposed to the CM (Shinagawa et al., 
2010). Although colon cancer cells were used, it was the only published study found that 
produced CM in a similar manner, as done in this study, by counting the cells before seeding to 
generate the CM. Additionally, CM was not diluted when added to the cells.  
Additional to understanding the possible proliferative capacity of the BM-MSC CM, further 
experiments were run to see if it had different effects to CM generated from another cell line. 
The same cell viability assay was run but this time using CM from a fibroblast cell line. As can 
be seen in Figure 4, the fibroblast CM did not significantly alter cell viability in either cell line. 
This is comparable to the results seen in the cells treated with BM-MSC CM as discussed above. 
From this it can be concluded that the effect MSC CM has on proliferation is not an isolated 
observation but is one that is similar across other cell lines. Similarly, umbilical cord MSC CM 
has also shown to have no effect on MDA-MB-231 cell proliferation, further supporting this 
observation (Li et al., 2017).  
Following on from the findings of the proliferation studies, the influence of MSC CM on 
migration and invasion could now be assessed with the knowledge that any observed changes 
were more likely to be caused by a change in the cells’ ability to migrate. In this study it was 
shown that both 1-Day and 5-Day CM significantly increased the migration of MDA-MB-231 
cells when compared to control (Fig. 5A). Five-Day CM was seen to enhance migration to a 
slightly more significant level compared to 1-Day CM. This suggests that the signaling 
molecule/s responsible for this effect are at a higher concentration after 5 days of incubation 
and that they are secreted continuously by the BM-MSCs rather than at one time point. The 
MCF-7 cell line responded in a much more limited way to the MSC CM showing only a 
negligible increase in migration by comparison (Fig. 5B). As mentioned previously, migration 
or the acquisition of a motile phenotype is one of the first stages of cancer metastasis hence 
why the current studies investigation started here. The Boyden chamber assay is able to assess 
a cell’s motility and as shown here it can be seen that CM from BM-MSCs is able to enhance 
this trait particularly in the MDA-MB-231 cell line. This cell line is known for being aggressive 
and easily capable of metastasis (Neve et al., 2006; Kenny et al., 2007). This leads to the 
conclusion that BM-MSC CM enhances motility rather than induces it. This is supported by the 
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results in the MCF-7 cell line which is known to have strong cell to cell adhesions and overall 
poor motility, as BM-MSC CM was seen to have no effect on the motility of this cell line 
(Kenny et al., 2007; Dittmer et al., 2009). This therefore, supports the theory that BM-MSC 
CM cannot induce a phenotypic change to induce motility but rather support an already existing 
ability to do so.  
Dittmer et al. (2009) demonstrated, in a 3D aggregation assay, the ability of MCF-7 cells to 
form tight cellular colonies due to strong cell-to-cell adhesion capabilities. When BM-MSCs 
were co-cultured with these MCF-7 cells they became more loosely attached to each other. 
When both cell lines were co-cultured in a Boyden chamber assay the migratory activity of the 
MCF-7 cells were significantly (p < 0.05) enhanced in comparison to MCF-7 cells seeded 
without BM-MSCs in the bottom chamber. These results match well with what was observed 
in our study whereby the presence of BM-MSCs in the bottom chamber significantly increased 
the migratory activity of the MCF-7 cell line (p = 0.0061) (Fig. 5B). This suggests that somehow 
the physical presence of the BM-MSCs is needed for the MCF-7 cell line to display any 
enhancement in motility. However, contrary to what was observed in this study, BM-MSC CM 
was seen to enhance MCF-7 motility to the same degree as the physical presence of BM-MSCs. 
A scratch assay revealed that after 48 hours (the same length of time as the Boyden chamber 
assay), MCF-7 cells exposed to BM-MSC CM significantly (p < 0.002) reduced the gap area 
up to 3-fold more than control. The MCF-7 cells co-cultured with the BM-MSCs resulted in the 
same outcome. It was disappointing to find that Dittmer et al. (2009) did not state how the CM 
was generated. However, the CM was diluted (1 part CM: 3 parts fresh media) and this simple 
difference could be why the results do not agree. Most studies do this because they fear 
undiluted CM will kill the cells and therefore affect the results. However, a simple cell viability 
test, as was conducted in this study, would confirm that is not the case. If anything when the 
results of our study and the work by Dittmer et al. (2009) are compared, it serves to suggest 
that BM-MSC CM inhibits MCF-7 motility as when it is diluted the cells are shown to have 
greater motility than when undiluted CM is used. It would be useful for a future study to conduct 
motility assays with a range of CM dilutions to see whether BM-MSC CM exerts a 
concentration dependent effect on MCF-7 motility.  
The results with the MDA-MB-231 cells in the Boyden chamber assay match up with what was 
observed in the scratch assay (Figures 5A and 6, respectively). In the scratch assay, the MDA-
MB-231 cells treated with BM-MSC CM were seen to have an enhanced ability to close the 
gap compared to control. This indicates the cells were made more motile. More importantly, it 
can be seen that the morphology of the cells changes when treated with BM-MSC CM. This 
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can be seen most prominently in the MDA-MB-231 cells exposed to 5-Day CM with the body 
of the cell being noticeably elongated (indicated by black arrows). This morphological change 
is indicative of enhanced motility and indicates that BM-MSC CM may enhance the motility of 
MDA-MB-231 by inducing cytoskeletal rearrangement. Shin et al. (2010) were able to prove 
that factors secreted by BM-MSCs induced actin polymerization in MDA-MB-231 cells which 
led to the same elongated morphology observed in the cells treated with BM-MSC CM in our 
study. Furthermore, it was also seen that these cells had an enhanced migratory capacity in the 
scratch assay model. Other studies have observed this same increase in migration in both of the 
scratch and Boyden chamber experimental systems. Goldstein et al. (2010) used the Boyden 
chamber system and after only 6 hours, MDA-MB-231 cells cultures with BM-MSC CM 
showed a significant (p < 0.001) enhancement in migration compared to control. This same 
result was also seen by Molloy et al. (2009) who ran the same experimental system for 18 hours.    
Dittmer et al. (2009) also reported the enhanced migration of MDA-MB-231 cells in a scratch 
assay. They noted that the cells were much more mobile than the MCF-7 cells even in the 
control conditions.  This is simply further evidence of the different metastatic potential of these 
two cell lines. With the addition of BM-MSC CM, the MDA-MB-231 cell line was capable of 
completely closing the gap within 24 hours which the MCF-7 cells failed to do even after 48 
hours. It was noted though that the BM-MSC CM enhanced the motility of the MCF-7 cell line 
more so than the MDA-MB-231 cell line. In the control conditions, MDA-MB-231 cells were 
capable of near complete gap closure after 24 hours. Therefore, complete gap closure with the 
addition of BM-MSC CM conveys that the enhancement of MDA-MB-231 motility was 
minimal. MCF-7 cells displayed very little migratory capability in the control conditions but 
with the addition of BM-MSC CM were able to achieve near complete gap closure. From this 
it was concluded that the migratory capability of MCF-7 cells was enhanced more so than the 
MDA-MB-231 cell line. This was the opposite of what was observed in our study. Although 
established models of migration were utilised in both studies, the experimental technique was 
different that drew these two contrary conclusions. This, and the fact that the CM was diluted 
in the study by Dittmer et al. (2009), mean direct comparisons are not possible. It is therefore 
difficult to conclusively know in what manner BM-MSC CM affects breast cancer cell motility 
in these cell lines.  
Adhesion to ECM proteins is a way cells are able to mobilise and migrate from the primary 
tumour (Gupta et al., 2006). Examples of such proteins are collagen I and fibronectin, which 
were used in this study to assess whether the adherence capabilities of breast cancer cells were 
altered by BM-MSC CM. BM-MSC CM did not significantly alter the adhesion of either cell 
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line to collagen I (Fig. 8). In the MCF-7 cell line there does appear to be a small increase in 
overall adhesion when the CM treated (both coated and uncoated) groups are compared to 
control (Fig. 8B). Perhaps BM-MSC CM does alter adhesion in some manner in this cell line 
just not in a collagen I specific way. In the MDA-MB-231 cell line, adhesion to fibronectin was 
less in all groups compared to relative controls although not in a statistically significant way 
(Fig. 9A). This may show that MDA-MB-231 cells are perhaps not very adherent to fibronectin 
but that is outside the scope of this study. The adhesion of MCF-7 cells was significantly 
increased in both 1-Day and 5-Day CM treated groups compared to the coated control group (p 
< 0.05) (Fig. 9B). However, in the serum free DMEM control group, MCF-7 cells are noticeably 
less adherent to fibronectin coated wells than uncoated. This suggests that BM-MSC CM may 
improve MCF-7 cell adhesion to fibronectin by restoring the cells’ ability to a level similar to 
what is observed in the uncoated control. In the other studies found which use BM-MSC CM 
on breast cancer cell lines, cell-matrix adhesions were not investigated as a possible mechanism 
for BM-MSC CM-mediated breast cancer migration. El-Haibi et al. (2012) did show via gene 
expression analysis that both MDA-MB-231 and MCF-7 cells upregulated genes associated 
with ECM receptor interaction when co-cultured with BM-MSCs. In particular, it was shown 
that lysyl oxidase (LOX) expression was significantly induced in both cell lines by the presence 
of MSCs (MDA-MB-231 p = 0.001, MCF-7 p = 0.008). LOX was shown to be critical for the 
adhesion of both cell lines to fibronectin (Payne et al., 2005). This does show how BM-MSCs 
are able to influence adhesion but the study did not do a comparison as to whether adhesion of 
breast cancer cell lines to ECM components was improved by the presence of BM-MSCs. Also, 
there was no adhesion assay with a BM-MSC treated and a non-treated group that can be 
directly compared to the observations of our study. However, this does show that BM-MSCs 
are capable of inducing signaling that aids in cell-matrix adhesions and that perhaps that is 
linked, in particular, to the restorative effect seen on the adhesion of MCF-7 cells to fibronectin 
in this study.  
Although there were no significant changes in adherence to collagen I in our study, others have 
shown that MSCs can influence the expression of discoidin domain receptor 2 (DDR2), a 
collagen receptor (Gonzalez et al., 2017). Gonzalez et al. (2017) co-cultured a number of 
different breast cancer cell lines including the MDA-MB-231 and MCF-7 cell lines with MSCs. 
There was over a 10-fold increase in the expression of DDR2 in both these cell lines. 
Furthermore, MDA-MB-231 cells cultured with MSCs were shown to cluster more closely to 
collagen. Though the studies presented here do not directly link to the experimental techniques 
used to assess adhesion to fibronectin and collagen they still provide insight into how BM-
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MSCs may alter the signaling associated with these ECM components. The studies showing 
MSC-induced LOX expression and DDR2 expression did show, using migration assays, that 
both were necessary for cell migration. Although the results from the current study do not 
suggest BM-MSC CM plays much of a role in cell-matrix adhesions, it is clear from the 
literature that BM-MSCs do aid in the cell signaling events associated with cell-matrix 
adhesion. To further investigate the effect of BM-MSC CM on breast cancer cell adhesion, 
future experiments could look into culturing the breast cancer cells in the CM and then 
analyzing the expression of cell surface receptors involved in cell-matrix adhesions. It is also 
possible that BM-MSC CM alters cell adhesion to other ECM constituents aside from collagen 
I and fibronectin so the same adhesion assays for those constituents could also be carried out.  
Another possible mechanism by which BM-MSC CM may influence the metastasic capabilities 
of breast cancer cells is by aiding invasion. Invasion involves the breakdown of basement 
membrane proteins which is facilitated by the secretion of proteases. To emulate this process 
in vitro, a hydrogel basement membrane formulation that is derived from mouse sarcoma cells 
is used, called Matrigel™. In our study, there was no significant change in invasive capability 
in either cell line (Fig. 7). MDA-MB-231 cells did show an elevated invasive capability but the 
large variation (as represented by the SEM error bars) meant no statistical significance was 
produced (Fig. 7A). This was a limitation in all the experiments within this study that used the 
Boyden chamber model. Resources were limited and as such future repeats are needed to further 
validate the results observed in both the invasion and migration assays within this study. 
Unfortunately, comparable studies could not be found that tested these breast cancer cell lines 
with this model in response to unmodified MSC CM. ‘Unmodified’ refers to CM that was 
harvested from MSCs that were not activated by any compound. The current study would be 
such an example. Conversely, Shin et al. (2010) exposed MSCs to TNF-α before harvesting 
CM. Despite these differences, Shin et al. (2010) was the only study found that used the same 
invasion model as the current one to assess MDA-MB-231 cells in response to MSC CM. In 
that study, MSC CM noticeably increased the invasion of this breast cancer cell line compared 
to treatment with control serum free media. No quantitative analysis was conducted so it is 
unknown if this change was statistically significant. However, the findings were further backed 
up by the observation that the expression of the proteases linked to invasion was also increased. 
MMP-2 and -9 showed 15- and 4-fold increases when treated with MSC CM compared to 
control serum free media (p < 0.05). This same increase was also observed for MMP-13 when 
MDA-MB-231 cells were co-cultured with MSCs (Karnoub et al., 2007). These investigations 
may help support our study’s observation that MSC CM can increase MDA-MB-231 invasion. 
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However, none of the studies provide definitive proof, due to small sample sizes or lack of 
proper statistical analysis. Disappointingly, no studies appear to exist that have analysed any 
invasive properties of MCF-7 cells in response to MSC CM with in vitro techniques.  
From the results of this study, it would appear that the metastatic properties of the MDA-MB-
231 cell line are influenced to a greater degree by MSC CM than the MCF-7 cell line. In making 
comparisons with studies published by others, it is hard to conclusively claim this, as only one 
other study comparably assessed both cell lines together and it claimed MCF-7 cell motility 
was enhanced to a greater degree by MSC CM (Dittmer et al., 2009). Ideally, additional studies 
that consider the influence of MSC CM on different breast cancer subtypes would be useful to 
help validate these observations. The other studies discussed here simply use the cell lines 
generically as examples of breast cancer and mostly fail to consider the differences that may 
occur between different subtypes. The main difference between these two subtypes is the 
expression of the oestrogen receptor (ER). Rhodes et al. (2010) found that when this receptor 
was inhibited in MCF-7 cells, the motility enhancements provided by co-culture with MSCs 
were significantly reduced (p < 0.001). This indicates that MSC CM may exert its effects on 
MCF-7 cells via an ER dependent mechanism which suggests that the response in MDA-MB-
231 cells must be achieved by different components in the CM as the cells do not express the 
ER. This difference could explain the varying responses observed in this and other studies when 
comparing the two cell lines.  
The model used here can also be questioned in terms of its validity in replicating the response 
that would be observed when these BM-MSCs are recruited to the tumour microenvironment. 
It is a possibility that once recruited to the tumour microenvironment, the cancer cells may alter 
the behaviour of the MSCs and what they secrete. The BM-MSC CM used in the experiments 
of the current study were taken from healthy MSCs in culture. Therefore, these cells are not 
necessarily representative of those that would be found in the tumour microenvironment. To 
assess the possibility of different behaviour between cancer ‘activated’ (actMSC) and normal 
healthy BM-MSCs (nMSC), BM-MSCs were cultured in breast cancer cell CM for 48 hours 
before being utilised in the Boyden chamber migration model (see section 2.8 for method 
details). In this model, the mobility of both breast cancer cell lines significantly increased when 
cultured with actMSCs, compared to nMSCs (Fig. 10). This result indicates that BM-MSCs 
‘activated’ by the breast cancer cell CM have enhanced abilities when it comes to increasing 
the mobility of breast cancer cells. Furthermore, when the motility of the actMSCs was 
assessed, it was observed that MCF7-actMSC motility significantly increased compared to 
nMSC (p < 0.05) (Fig. 11). The motility of the MDA-MB-231-actMSCs also increased although 
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not significantly. This was due to the lack of statistical power owing to the small sample size. 
Together the results of both the cancer cell migration and actMSC migration experiments 
indicate an altered behaviour in the actMSCs. This suggests that using healthy BM-MSCs from 
culture or generating CM from these healthy BM-MSCs does not represent those BM-MSCs 
which would be found in the tumour microenvironment. Unfortunately, not enough actMSCs 
could be generated to redo all the previously run in vitro experiments that were part of this 
study.  
The findings of these actMSCs may also help to explain the difference that is observed between 
BM-MSC 1-Day CM and the MSC control group in the migration and invasion assays discussed 
earlier (Figures 5 and 7). Both groups represent the BM-MSC secretome profile of 1-Day CM, 
yet across all those experiments, the two groups produce unequal results. However, the MSC 
control group cells will be ‘activated’ by the presence of the cancer cells in this co-culture 
method. And as seen in the results of the actMSC experiments, this will change the cells’ 
behaviour.  
Molloy et al. (2009) and Rhodes et al. (2010) also considered the effect of the tumour 
microenvironment on the behavior of BM-MSCs. In the study by Molloy et al. (2009), cells 
were first exposed to TNF-α (10 ng/ml), as it is prominent in the tumour microenvironment 
(Charles et al., 2009). After 24 hours there was a significant increase in the expression of 
CXCL-9, -10 and -11 in the BM-MSCs treated with TNF-α compared to untreated cells (8.2, 
628 and 87.2 fold increases, respectively; p < 0.05). Rhodes et al. (2010) noted that the 
proliferative capacity of MCF-7 cells was significantly reduced when exposed to ‘naïve’ MSC 
CM, compared to those MCF-7 cells co-cultured with MSCs (p < 0.01). Together with the 
findings in the current study, it can be seen that healthy ‘naïve’ BM-MSCs are not representative 
of the BM-MSCs located in the tumour microenvironment. It would be difficult to replicate all 
the components contributing to the tumour microenvironment with in vitro techniques. 
However, simple changes in technique like the ‘activation’ carried out in this study will make 
the in vitro results more comparable to the in vivo conditions. 
An additional limitation within our study is one that is debated amongst researchers in this field 
(unpublished). That is the time allowed for CM generation in serum free media. It is argued that 
beyond 2-3 days the cells will start dying due to lack of nutrients resulting in high levels of cell 
death material. In our study, we showed that 5-Day CM did not cause cell death, which was a 
concern raised within this field. Future work could assess the viability of MSCs cultured in 
serum free media for five days to assess how healthy the cells remain.  
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4.1 Overall Conclusion 
The results from our study help contribute to the thus far conflicting story of how BM-MSCs 
influence the metastasis of breast cancer cells. The results do indicate that cellular motility is 
the most clearly influenced process amongst those investigated as both cell lines consistently 
showed a significant increase in motility, as assessed in the Boyden chamber model and scratch 
assay (Figures 5 and 6). Furthermore, these in vitro results support the observations made by 
those in vivo studies that reported an increase in the metastatic nodules of mice whose primary 
tumours were additionally exposed to BM-MSCs (Karnoub et al., 2007; Albarenque et al., 
2011). Karnoub et al. (2007) did however report a 4-fold increase in the growth kinetics of the 
MCF-7 cell line when co-injected with BM-MSCs which this study did not show. It is therefore 
possible that in an intact system, the influence of BM-MSCs on MCF-7 cell metastasis is due 
to cell proliferation and not cell motility as was shown in this study. It could also be that both 
MCF-7 cell motility and proliferation are influenced concomitantly by BM-MSCs. The growth 
kinetics of the MDA-MB-231 cell line exposed to BM-MSCs was uniform across both in vitro 
and in vivo methods. Overall though, our study shows that the observed BM-MSC-induced 
increase in breast cancer metastasis in vivo could be driven by enhanced cell motility aiding in 
the migration phase of metastasis. This confirms the hypothesis that the breast cancer cell lines 
would respond differently compared to controls. Furthermore, it supports the in vivo evidence 
that shows BM-MSCs increase breast cancer metastasis.   
4.2 Future Studies 
Future directions for our study would include analysing the effect of the BM-MSC CM in more 
detail. A dilution series would provide better insight into whether a concentration dependent 
effect is exerted by the secretome of the BM-MSCs. To do this CM would be generated the 
same way but additional treatment groups would be added to the cell viability assay design. 
Though it is presumed the 1 and 5 Day CM batches contain different concentrations of 
secretome factors, this concentration aid in validating that hypothesis.  
Given that the actMSCs were shown to significantly increase the migration of both breast cancer 
cell lines, repeating the remainder of the experiments, originally carried out with nMSCs but 
with actMSC CM instead, would give further insight into the differences between nMSCs and 
actMSCs. Comparing the actMSCs, generated with the current method, to a primary MSC cell 
line extracted from a breast cancer tumour would also validate how representative the MSCs 
used in culture are to stromal cancer MSCs. Furthermore, if further in vivo studies were 
performed, markers of cellular motility and cytoskeletal changes could be explored to help 
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confirm the evidence presented in this in vitro study that BM-MSCs increase breast cancer 
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